These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

745 related articles for article (PubMed ID: 20304682)

  • 41. Epidemiology and morbidity of Epstein-Barr virus infection in pediatric renal transplant recipients: a multicenter, prospective study.
    Höcker B; Fickenscher H; Delecluse HJ; Böhm S; Küsters U; Schnitzler P; Pohl M; John U; Kemper MJ; Fehrenbach H; Wigger M; Holder M; Schröder M; Billing H; Fichtner A; Feneberg R; Sander A; Köpf-Shakib S; Süsal C; Tönshoff B
    Clin Infect Dis; 2013 Jan; 56(1):84-92. PubMed ID: 23042966
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Case-control study of risk factors for the development of post-transplant lymphoproliferative disease in a pediatric heart transplant cohort.
    Katz BZ; Pahl E; Crawford SE; Kostyk MC; Rodgers S; Seshadri R; Proytcheva M; Pophal S
    Pediatr Transplant; 2007 Feb; 11(1):58-65. PubMed ID: 17239124
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation.
    Maecker B; Jack T; Zimmermann M; Abdul-Khaliq H; Burdelski M; Fuchs A; Hoyer P; Koepf S; Kraemer U; Laube GF; Müller-Wiefel DE; Netz H; Pohl M; Toenshoff B; Wagner HJ; Wallot M; Welte K; Melter M; Offner G; Klein C
    J Clin Oncol; 2007 Nov; 25(31):4902-8. PubMed ID: 17971586
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Roles of Epstein-Barr virus viral load monitoring in the prediction of posttransplant lymphoproliferative disorder in pediatric liver transplantation.
    Chen HS; Ho MC; Hu RH; Wu JF; Chen HL; Ni YH; Hsu HY; Jeng YM; Chang MH
    J Formos Med Assoc; 2019 Sep; 118(9):1362-1368. PubMed ID: 30612881
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association between Epstein-Barr virus seroconversion and immunohistochemical changes in tonsils of pediatric solid organ transplant recipients.
    Shapiro NL; Tang CG; Bhattacharyya N
    Laryngoscope; 2011 Aug; 121(8):1718-25. PubMed ID: 21792960
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.
    Colombini E; Guzzo I; Morolli F; Longo G; Russo C; Lombardi A; Merli P; Barzon L; Murer L; Piga S; Ciofi Degli Atti ML; Locatelli F; Dello Strologo L
    Pediatr Nephrol; 2017 Aug; 32(8):1433-1442. PubMed ID: 28280938
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of immunosuppression regimen in post-transplant lymphoproliferative disorder in pediatric heart transplant patients.
    Dayton JD; Richmond ME; Weintraub RG; Shipp AT; Orjuela M; Addonizio LJ
    J Heart Lung Transplant; 2011 Apr; 30(4):420-5. PubMed ID: 21147001
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Transplantation for congenital heart disease is associated with an increased risk of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in children.
    Offor UT; Bacon CM; Roberts J; Powell J; Brodlie M; Wood K; Windebank KP; Flett J; Hewitt T; Rand V; Hasan A; Parry G; Gennery AR; Reinhardt Z; Bomken S
    J Heart Lung Transplant; 2021 Jan; 40(1):24-32. PubMed ID: 33339556
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epstein-Barr virus--associated posttransplantation lymphoproliferative disorder with tacrolimus metabolism deterioration in infants after living-donor liver transplantation.
    Fukushima D; Sato K; Kawagishi N; Ohuchi N; Satomi S
    Transplantation; 2015 Jan; 99(1):114-9. PubMed ID: 24846306
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients.
    Ganschow R; Schulz T; Meyer T; Broering DC; Burdelski M
    J Pediatr Gastroenterol Nutr; 2004 Feb; 38(2):198-203. PubMed ID: 14734884
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The value of prospective monitoring of Epstein-Barr virus DNA in blood samples of pediatric liver transplant recipients.
    Scheenstra R; Verschuuren EA; de Haan A; Slooff MJ; The TH; Bijleveld CM; Verkade HJ
    Transpl Infect Dis; 2004 Mar; 6(1):15-22. PubMed ID: 15225222
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Epstein-Barr virus load in transplant patients: Early detection of post-transplant lymphoproliferative disorders.
    Fellner MD; Durand KA; Solernou V; Bosaleh A; Balbarrey Z; García de Dávila MT; Rodríguez M; Irazu L; Alonio LV; Picconi MA
    Rev Argent Microbiol; 2016; 48(2):110-8. PubMed ID: 27157146
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Surveillance of Epstein-Barr virus loads in adult liver transplantation: associations with age, sex, posttransplant times, and transplant indications.
    Schaffer K; Hassan J; Staines A; Coughlan S; Holder P; Tuite G; McCormick AP; Traynor O; Hall WW; Connell J
    Liver Transpl; 2011 Dec; 17(12):1420-6. PubMed ID: 21837744
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Soluble CD30: a serum marker for Epstein-Barr virus-associated lymphoproliferative diseases.
    Haque T; Chaggar T; Schafers J; Atkinson C; McAulay KA; Crawford DH
    J Med Virol; 2011 Feb; 83(2):311-6. PubMed ID: 21181928
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation.
    Liu QF; Fan ZP; Luo XD; Sun J; Zhang Y; Ding YQ
    Transpl Infect Dis; 2010 Aug; 12(4):284-91. PubMed ID: 20345506
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts.
    Hoegh-Petersen M; Goodyear D; Geddes MN; Liu S; Ugarte-Torres A; Liu Y; Walker JT; Fonseca K; Daly A; Duggan P; Stewart D; Russell JA; Storek J
    Bone Marrow Transplant; 2011 Aug; 46(8):1104-12. PubMed ID: 21057556
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Asymptomatic high Epstein-Barr viral load carriage in pediatric renal transplant recipients.
    Tanaka E; Sato T; Ishihara M; Tsutsumi Y; Hisano M; Chikamoto H; Akioka Y; Dohno S; Maeda A; Hattori M; Wakiguchi H; Fujieda M
    Pediatr Transplant; 2011 May; 15(3):306-13. PubMed ID: 21492352
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation.
    Orjuela MA; Alobeid B; Liu X; Siebert AL; Kott ER; Addonizio LJ; Morris E; Garvin JH; Lobritto SJ; Cairo MS
    Br J Haematol; 2011 Mar; 152(6):733-42. PubMed ID: 21275950
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characteristics of early and late PTLD development in pediatric solid organ transplant recipients.
    Schober T; Framke T; Kreipe H; Schulz TF; Großhennig A; Hussein K; Baumann U; Pape L; Schubert S; Wingen AM; Jack T; Koch A; Klein C; Maecker-Kolhoff B
    Transplantation; 2013 Jan; 95(1):240-6. PubMed ID: 23222898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.